
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen is a small-cap medical technology company, primarily deriving revenue from its AVISE brand testing products used for diagnosis, prognosis, and monitoring of rheumatic diseases. Challenges facing the company include commercial execution risks, payor concentration risks, and regulatory risks; however, we believe the company is well-positioned for long-term growth and expect continued volume and revenue growth despite near-term ASP declines. With a strong focus on expanding territories and achieving positive free cash flow in 2027, we rate Exagen as a Buy with a price target of $8 per share.
Bears say
Exagen is a company with a strong focus on the medical technology sector, specifically in diagnostic testing for autoimmune diseases. However, with a decrease in projected revenue growth in the long term and potential challenges with obtaining adequate reimbursement from third-party payers, the company may face difficulties in achieving profitability. Additionally, its reliance on a single laboratory facility and its significant debt obligations could pose risks in the future.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares